Letrozin (Letrozole)

Letrozole works by selectively blocking the aromatase enzyme, which converts androgens into estrogens in peripheral tissues. This inhibition markedly reduces circulating estrogen, depriving estrogen‑dependent cancer cells of a key growth signal.

The dose of Letrozin is determined by the prescribing physician based on the patient’s clinical condition, treatment setting, and tolerance. Typical regimens follow established oncology guidelines, but the exact amount and schedule must be individualized by a qualified healthcare professional.

Letrozin is classified as contraindicated in pregnancy because it can interfere with fetal estrogen synthesis. Its safety during breastfeeding has not been established, and breastfeeding is generally not recommended while taking the medication.

To order Letrozin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Letrozin (letrozole) is a third‑generation aromatase inhibitor with a long half‑life and potent estrogen suppression. Compared with anastrozole, another commonly used inhibitor, letrozole often provides slightly greater estrogen reduction but may have a higher incidence of bone‑related side effects, requiring careful monitoring.

Letrozin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and out of reach of children.

Letrozin is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their healthcare provider.

Serious risks include severe liver injury, bone fractures due to decreased bone density, deep‑vein thrombosis or pulmonary embolism, and cardiovascular events such as hypertension or arrhythmias. Patients should be monitored regularly for these complications.

Letrozin should not be used by premenopausal women, pregnant or nursing individuals, patients with known hypersensitivity to letrozole or any component of the formulation, and those with severe liver impairment without appropriate medical supervision.